The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

After the physician sued the nurse, and all the required discovery was completed, the nurse moved to dismiss the case in its entirety. The physician opposed the motion to dismiss and the court ...

NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

(HealthDay News) — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next 5 years, according to research published in the ...

The researchers projected that more than 42,000 deaths could be averted annually, including more than 11,000 among those with type 2 diabetes, with expanded access. (HealthDay News) — Expanding access ...

One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

Credit: Journey Medical Corporation. The approval was supported by data from 2 randomized, double-blind, active- and ...

Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps ...

Increased relative risk for adverse events seen among those admitted during weeks with high versus low COVID-19 burden ...

The FDA has issued a proposal to remove a common decongestant in over the counter products.